T
Trastuzumab Emtansine [Kadcyla]
Availability of ACE Drug Guidance
Yes
Biologics Drug Information Overview
No
Post-marketing information
Dear Healthcare Professional Letters
Subsidy Information and Financing Scheme
Cancer Drug and Clinical Indication listed in the MediShield Life Outpatient Cancer Drug List
Active ingredient: Trastuzumab Emtansine
General information
Subsidy Information and Financing Scheme
[MSHL] Trastuzumab Emtansine Powder For Concentrate For Solution For Infusion 100 mg, 160 mg
Adjuvant treatment of HER2 positive early breast cancer in patients with residual invasive disease, after neoadjuvant treatment with trastuzumab and a taxane. Maximum 14 cycles.
Treatment of HER2-positive, locally advanced, unresectable, or metastatic breast cancer in patients who have received prior treatment with trastuzumab and chemotherapy.
Drug Guidance for Subsidy
01/09/2023 Review of cancer drugs for treating early or advanced HER2-positive breast cancer
[NR] The Ministry of Health’s Drug Advisory Committee has not recommended listing pertuzumab, pertuzumab plus trastuzumab fixed-dose subcutaneous (SC) injection, trastuzumab emtansine or tucatinib on the Medication Assistance Fund (MAF) for treating human epidermal growth factor receptor (HER2)-positive breast cancer due to unfavourable cost-effectiveness at the prices proposed by the manufacturer.
Clinical indications, subsidy class and MediShield Life claim limits for all drugs included in the evaluation are provided in the Annex.
Post Marketing Information
General Availability in Public Healthcare Institution
Note:
General availability information reflected is based on the Public Healthcare Institutions’ (PHI) formulary on what is commonly used for treating their patient population and may or may not be available for patients not under the care of that institution. It does not reflect the PHI’s actual inventory availability and is subjected to change. Please consult the Public Hospitals or Polyclinics for details on availability and supply restrictions/considerations. General availability is not tied to any brand unless otherwise stated.
Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration
Availability information
Formulation | Public Healthcare Institution |
|---|---|
Kadcyla Powder For Concentrate For Solution For Infusion 100 mg |
|
Kadcyla Powder For Concentrate For Solution For Infusion 160 mg |
|
Registered Product(s) Information
Clinical and product info
Clinical info | Product Info |
|---|---|
Information under the Indication, Dosage and Contraindication sections are extracted from the relevant Package Insert/Patient Information Leaflet of the product available on HSA Infosearch. For more information, please refer to the product's Package Insert/ Patient Information Leaflet available on HSA Infosearch. The information provided is for informational purposes only, and is not exhaustive. The information provided is not a substitute for professional medical advice. Please consult a qualified healthcare provider for any medical advice. | Information available here are product details as registered with the HSA. As this website is updated monthly, please refer to HSA Infosearch for the most updated product information. |
Intravenous
KADCYLA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/VIAL [SIN14497P]*
KADCYLA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 160MG/VIAL [SIN14496P]*
* Clinical information is available for this product.